SCHEMBL24328293

SCHEMBL24328293

Fc1ccc(Nc2nc(Cl)ncc2Cl)c2c1CCN2

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 4/20 0.33
KMT2A Q03164 1/20 0.33
ALDH1A1 P00352 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ROCK2 O75116 2/20 0.31
PTK2 Q05397 1/20 0.31
CCNA2 P20248 3/20 0.31
CDK2 P24941 3/20 0.31
CCNK O75909 2/20 0.31
CCND3 P30281 2/20 0.31
CDK9 P50750 2/20 0.31
CDK6 Q00534 2/20 0.31
EGFR P00533 1/20 0.31
KDR P35968 1/20 0.31
AURKA O14965 1/20 0.30
MAP4K1 Q92918 1/20 0.30
MAPK9 P45984 2/20 0.30
MAPK10 P53779 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29661462 1.00 ALK (0.33) ALKKMT2AALDH1A1L3MBTL1ROCK2
SCHEMBL29661304 0.85 CCNA2 (0.38) ALKCCNA2CDK2CCNKCCND3
SCHEMBL24327455 0.85 IGF1R (0.35) ALKKMT2ACCNA2CDK2CCNK
SCHEMBL24327015 0.85 CCNA2 (0.38) ALKCCNA2CDK2CCNKCCND3
SCHEMBL24327456 0.85 ALK (0.32) ALK
SCHEMBL29661395 0.78 MAP4K1 (0.38) ALKCCNA2CDK2CCNKCCND3
SCHEMBL24327605 0.78 MAP4K1 (0.38) ALKCCNA2CDK2CCNKCCND3
SCHEMBL24620296 0.76 TYK2 (0.39) KMT2APTK2MAP4K1
SCHEMBL24326998 0.74 ALK (0.35) ALKKMT2ACCNA2CDK2CCNK
SCHEMBL24327013 0.73 INSR (0.39) ALKCCNA2CDK2CCNKCCND3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
CN-116249690-A Indoline compounds and derivatives as EGFR inhibitors 百济神州有限公司 2023-06-09 CN disclosed
WO-2022063106-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEIGENE, LTD. (KY) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS EGFR, ERBB2, ERBB4 ALK 13/4885KMT2A 2570/4885ALDH1A1 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.